The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

被引：107

作者：

Fruchart, Jean-Charles ^{[1
]}

Santos, Raul D. ^{[2
,3
]}

Aguilar-Salinas, Carlos ^{[4
,5
]}

Aikawa, Masanori ^{[6
,7
,8
]}

Al Rasadi, Khalid ^{[9
]}

Amarenco, Pierre ^{[10
,11
]}

Barter, Philip J. ^{[12
]}

Ceska, Richard ^{[13
,14
]}

Corsini, Alberto ^{[15
]}

Despres, Jean-Pierre ^{[16
]}

Duriez, Patrick ^{[17
]}

Eckel, Robert H. ^{[18
]}

Ezhov, Marat V. ^{[19
]}

Farnier, Michel ^{[20
,21
]}

Ginsberg, Henry N. ^{[22
]}

Hermans, Michel P. ^{[23
,24
]}

Ishibashi, Shun ^{[25
]}

Karpe, Fredrik ^{[26
,27
]}

Kodama, Tatsuhiko ^{[28
]}

Koenig, Wolfgang ^{[29
,30
,31
]}

Krempf, Michel ^{[32
,33
,34
]}

Lim, Soo ^{[35
,36
]}

Lorenzatti, Alberto J. ^{[37
,38
]}

McPherson, Ruth ^{[39
]}

Millan Nunez-Cortes, Jesus ^{[40
,41
,42
]}

Nordestgaard, Borge G. ^{[43
,44
,45
,46
]}

Ogawa, Hisao ^{[47
]}

Packard, Chris J. ^{[48
]}

Plutzky, Jorge ^{[49
]}

Ponte-Negretti, Carlos I. ^{[50
]}

Pradhan, Aruna ^{[51
,52
]}

Ray, Kausik K. ^{[53
]}

Reiner, Zeljko ^{[54
]}

Ridker, Paul M. ^{[55
,56
]}

Ruscica, Massimiliano ^{[15
]}

Sadikot, Shaukat ^{[57
]}

Shimano, Hitoshi ^{[58
]}

Sritara, Piyamitr ^{[59
]}

Stock, Jane K. ^{[1
]}

Su, Ta-Chen ^{[60
,61
]}

Susekov, Andrey V. ^{[62
]}

Tartar, Andre ^{[63
]}

Taskinen, Marja-Riitta ^{[64
,65
]}

Tenenbaum, Alexander ^{[66
,67
]}

Tokgozoglu, Lale S. ^{[68
]}

Tomlinson, Brian ^{[69
]}

Tybjaerg-Hansen, Anne ^{[70
,71
,72
,73
]}

Valensi, Paul ^{[74
]}

Vrablik, Michal ^{[75
,76
]}

Wahli, Walter ^{[77
,78
,79
]}

机构：

[1] R3i Fdn, Picassopl 8, CH-4010 Basel, Switzerland

[2] Univ Sao Paulo, Hosp Israelita Albert Einstein, Med Sch Hosp, Sao Paulo, Brazil

[3] Univ Sao Paulo, Med Sch Hosp, Heart Inst InCor, Lipid Clin, Sao Paulo, Brazil

[4] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Endocrinolgy & Metab, Unidad Invest Enfermedades Metabol, Mexico City, DF, Mexico

[5] Escuela Med & Ciencias Salud, Tecnol Monterrey, Monterrey, Mexico

[6] Harvard Med Sch, Brigham & Womens Hosp, Ctr Interdisciplinary Cardiovasc Sci, Boston, MA 02115 USA

[7] Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc Med, Ctr Excellence Vasc Biol, Boston, MA 02115 USA

[8] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA

[9] Sultan Qaboos Univ Hosp, Dept Clin Biochem, Muscat, Oman

[10] Paris Diderot Sorbonne Univ, Dept Neurol, Paris, France

[11] Paris Diderot Sorbonne Univ, Stroke Ctr, Paris, France

[12] Univ New South Wales, Sch Med Sci, Lipid Res Grp, Sydney, NSW, Australia

[13] Univ Gen Hosp, Internal Med Clin 3, Ctr Prevent Cardiol, Dept Int Med 3, Prague, Czech Republic

[14] Charles Univ Prague, Prague, Czech Republic

[15] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy

[16] Univ Laval, Univ Laval CIUSSS Capitale Natl, Ctr Rech Soins & Serv Premiere Ligne, Dept Kinesiol,Fac Med, Quebec City, PQ, Canada

[17] Univ Lille, CHU Lille, INSERM,UDSL, U1171 Degenerat & Vasc Cognit Disorders,Fac Pharm, Lille, France

[18] Univ Colorado, Sch Med, Dept Med, Div Endocrinol Metab & Diabet, Anschutz Med Campus, Aurora, CO USA

[19] Natl Cardiol Res Ctr, Lab Lipid Disorders, Moscow, Russia

[20] CHU Dijon Bourgogne, Lipid Clin, Point Med, Dijon, France

[21] CHU Dijon Bourgogne, Dept Cardiol, Dijon, France

[22] Columbia Univ, Vagelos Coll Physicians & Surg, New York, NY USA

[23] Catholic Univ Louvain, Clin Univ St Luc, Div Nutr & Endocrinol, Brussels, Belgium

[24] Catholic Univ Louvain, IREC, Brussels, Belgium

[25] Jichi Med Univ, Dept Internal Med, Div Endocrinol & Metab, Shimotsuke, Tochigi, Japan

[26] Univ Oxford, OCDEM, Oxford, England

[27] Churchill Hosp, OUH Fdn Trust, NIHR Oxford Biomed Res Ctr, Oxford, England

[28] Univ Tokyo, Ctr Adv Sci & Technol, Lab Syst Biol & Med Res, Tokyo, Japan

[29] Tech Univ Munich, Deutsch Herzzentrum Munchen, Munich, Germany

[30] DZHK German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, Munich, Germany

[31] Univ Ulm, Inst Epidemiol & Med Biometry, Ulm, Germany

[32] Hop Hotel Dieu, West Human Nutr Res Ctr CRNHO, Mass Spectrometry Core facil, Nantes, France

[33] INRA, UMR 1280, Physiol Adaptat Nutr, Nantes, France

[34] G&R Laennec Hosp, Dept Endocrinol Metab Dis & Nutr, Nantes, France

[35] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam, South Korea

[36] Seoul Natl Univ, Coll Med, Seongnam, South Korea

[37] Rusculleda Fdn Res, DAMIC Med Inst, Cordoba, Argentina

[38] Cordoba Hosp, Cardiol Dept, Cordoba, Argentina

[39] Univ Ottawa, Heart Inst, Ruddy Canadian Cardiovasc Genet Ctr, Ottawa, ON, Canada

[40] Gregorio Maranon Univ Hosp, Lipids Unit, Internal Med, Madrid, Spain

[41] Univ Complutense Madrid, Sch Med, Dept Med, Madrid, Spain

[42] Inst Invest Sanitarias Gregorio Maranon, Madrid, Spain

[43] Dept Clin Biochem, Herlev, Denmark

[44] Copenhagen Univ Hosp, Gentofte Hosp, Herlev, Denmark

[45] Copenhagen Gen Populat Study, Herlev, Denmark

[46] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark

[47] Natl Cerebral & Cardiovasc Ctr, Suita, Osaka, Japan

[48] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland

[49] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Med, Boston, MA 02115 USA

[50] Hosp El Pino Santiago Chile, Serv Cardiol, Unidad Prevenc Cardiometab Cardiocob, Soc Inter Amer Cardiol SIAC Chairma Cardiovasc Pr, Santiago, Chile

来源：

CARDIOVASCULAR DIABETOLOGY | 2019年 / 18卷 / 1期

关键词：

Residual cardiovascular risk; Visceral obesity; Diabetes; Atherogenic dyslipidemia; Triglycerides; Remnant cholesterol; Selective peroxisome proliferator-activated receptor alpha modulator; SPPARMalpha; Pemafibrate (K-877); Inflammation; PROMINENT; DENSITY-LIPOPROTEIN CHOLESTEROL; FATTY LIVER-DISEASE; ISCHEMIC-HEART-DISEASE; ALL-CAUSE MORTALITY; TRIGLYCERIDE-RICH LIPOPROTEINS; COMBINATION LIPID THERAPY; TISSUE FACTOR EXPRESSION; ACUTE-CORONARY-SYNDROME; OF-FUNCTION MUTATIONS; CARDIOVASCULAR-DISEASE;

D O I：

10.1186/s12933-019-0864-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARM) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARM agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARM agonist safely reduces residual cardiovascular risk.

引用

页数：20

共 148 条

[1] Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases [J].

Adams, Leon A. ;

Anstee, Quentin M. ;

Tilg, Herbert ;

Targher, Giovanni .

GUT, 2017, 66 (06) :1138-1153

[2] Overproduction of large VLDL particles is driven by increased liver fat content in man [J].

Adiels, M ;

Taskinen, MR ;

Packard, C ;

Caslake, MJ ;

Soro-Paavonen, A ;

Westerbacka, J ;

Vehkavaara, S ;

Hakkinen, A ;

Olofsson, SO ;

Yki-Jarvinen, H ;

Borén, J .

DIABETOLOGIA, 2006, 49 (04) :755-765

[3] Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial [J].

Anand, Sonia S. ;

Bosch, Jackie ;

Eikelboom, John W. ;

Connolly, Stuart J. ;

Diaz, Rafael ;

Widimsky, Peter ;

Aboyans, Victor ;

Alings, Marco ;

Kakkar, Ajay K. ;

Keltai, Katalin ;

Maggioni, Aldo P. ;

Lewis, Basil S. ;

Stoerk, Stefan ;

Zhu, Jun ;

Lopez-Jaramillo, Patricio ;

O'Donnell, Martin ;

Commerford, Patrick J. ;

Vinereanu, Dragos ;

Pogosova, Nana ;

Ryden, Lars ;

Fox, Keith A. A. ;

Bhatt, Deepak L. ;

Misselwitz, Frank ;

Varigos, John D. ;

Vanassche, Thomas ;

Avezum, Alvaro A. ;

Chen, Edmond ;

Branch, Kelley ;

Leong, Darryl P. ;

Bangdiwala, Shrikant I. ;

Hart, Robert G. ;

Yusuf, Salim .

LANCET, 2018, 391 (10117) :219-229

[4] Diverse Roles of Mitochondria in Immune Responses: Novel Insights Into Immuno-Metabolism [J].

Angajala, Anusha ;

Lim, Sangbin ;

Phillips, Joshua B. ;

Kim, Jin-Hwan ;

Yates, Clayton ;

You, Zongbing ;

Tan, Ming .

FRONTIERS IN IMMUNOLOGY, 2018, 9

[5]

[Anonymous], 2000, JAMA, DOI DOI 10.1001/jama.2009.1619

[6]

[Anonymous], 2015, EUR HEART J S1

[7] Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial [J].

Arai, Hidenori ;

Yamashita, Shizuya ;

Yokote, Koutaro ;

Araki, Eiichi ;

Suganami, Hideki ;

Ishibashi, Shun .

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2018, 25 (06) :521-538

[8] Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia [J].

Arai, Hidenori ;

Yamashita, Shizuya ;

Yokote, Koutaro ;

Araki, Eiichi ;

Suganami, Hideki ;

Ishibashi, Shun .

ATHEROSCLEROSIS, 2017, 261 :144-152

[9] Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial [J].

Araki, Eiichi ;

Yamashita, Shizuya ;

Arai, Hidenori ;

Yokote, Koutaro ;

Satoh, Jo ;

Inoguchi, Toyoshi ;

Nakamura, Jiro ;

Maegawa, Hiroshi ;

Yoshioka, Narihito ;

Tanizawa, Yukio ;

Watada, Hirotaka ;

Suganami, Hideki ;

Ishibashi, Shun .

DIABETES CARE, 2018, 41 (03) :538-546

[10] The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice [J].

Araki, Masaya ;

Nakagawa, Yoshimi ;

Oishi, Asayo ;

Han, Song-iee ;

Wang, Yunong ;

Kumagai, Kae ;

Ohno, Hiroshi ;

Mizunoe, Yuhei ;

Iwasaki, Hitoshi ;

Sekiya, Motohiro ;

Matsuzaka, Takashi ;

Shimano, Hitoshi .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (07)

← 1 2 3 4 5 6 7 8 9 10 →